OMB
.report
Search
IMPROVE Study Phase 2
Data to Support Drug Product Communications as Used by the FDA
OMB: 0910-0695
IC ID: 224206
OMB.report
HHS/FDA
OMB 0910-0695
ICR 201711-0910-001
IC 224206
( )
⚠️ Notice: This information collection may be referencing outdated material. More recent filings for OMB 0910-0695 can be found here:
2024-03-07 - Extension without change of a currently approved collection
2022-06-30 - No material or nonsubstantive change to a currently approved collection
Documents and Forms
Document Name
Document Type
FDA IMPROVE SURVEY.pdf
Other-IMPROVE Survey Instrument
FDA IMPROVE Screener.pdf
Other-IMPROVE Survey Screener
FDA IMPROVE PHASE 2 SS.pdf
IMPROVE Study Phase 2 Supporting Statement
IC Document
FDA IMPROVE Screener Revised 12-19 tracked changes.pdf
Revised Screener
IC Document
FDA IMPROVE Screener Revised 12-19 clean.pdf
Revised Screener clean version
IC Document
OMB Amendment Screener Memo 12-19.pdf
Non Sub Request Memo re. Screener Revisions
IC Document
Information Collection (IC) Details
View Information Collection (IC)
IC Title:
IMPROVE Study Phase 2
Agency IC Tracking Number:
CDER
IC Status:
Unchanged
Obligation to Respond:
Voluntary
CFR Citation:
Information Collection Instruments:
Document Type
Form No.
Form Name
Instrument File
URL
Available Electronically?
Can Be Submitted Electronically?
Electronic Capability
Other-IMPROVE Survey Instrument
FDA IMPROVE SURVEY.pdf
Yes
Yes
Fillable Fileable
Other-IMPROVE Survey Screener
FDA IMPROVE Screener.pdf
Yes
Yes
Fillable Fileable
Federal Enterprise Architecture Business Reference Module
Line of Business:
Health
Subfunction:
Consumer Health and Safety
Privacy Act System of Records
Title:
FR Citation:
Number of Respondents:
850
Number of Respondents for Small Entity:
0
Affected Public:
Individuals or Households
Percentage of Respondents Reporting Electronically:
100 %
Requested
Program Change Due to New Statute
Program Change Due to Agency Discretion
Change Due to Adjustment in Agency Estimate
Change Due to Potential Violation of the PRA
Previously Approved
Annual Number of Responses for this IC
850
0
0
0
0
850
Annual IC Time Burden (Hours)
170
0
0
0
0
170
Annual IC Cost Burden (Dollars)
0
0
0
0
0
0
Documents for IC
Title
Document
Date Uploaded
IMPROVE Study Phase 2 Supporting Statement
FDA IMPROVE PHASE 2 SS.pdf
10/30/2016
Revised Screener
FDA IMPROVE Screener Revised 12-19 tracked changes.pdf
01/19/2017
Revised Screener clean version
FDA IMPROVE Screener Revised 12-19 clean.pdf
01/19/2017
Non Sub Request Memo re. Screener Revisions
OMB Amendment Screener Memo 12-19.pdf
01/19/2017
Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.